Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
In April 2024, the world's longest-running global conference on Alzheimer's disease and dementia came to Kraków, Poland, to provide the latest insights, innovations and inspirations on dementia over three days, six plenary sessions, 29 parallel sessions and eight symposiums to over 1000 delegates representing over 100 countries.
This year, 2024 marks the 40th year of Alzheimer's Disease International and our work to secure a future that includes greater awareness of the condition, increased access to care, post-diagnostic support,and emerging treatments as well as a achieving a world without stigma. ADI invites our global community to celebrate with us on this momentous occasion with thanks to all who have been with us on this journey over four decades.
With only a fifth of WHO Member States meeting their commitments to the Global Action Plan on dementia, urgent action is needed to address the escalating global dementia crisis.
ADI member Dementia Australia has developed an app to help support brain health and encourage more timely dementia diagnoses.
As ADI prepares to attend the G7 summit in Hiroshima, Japan, DY Suharya writes about the journey of making dementia a priority at the G7 summit.
The month of March has marked significant progress in the development and implementation of National Dementia Plans (NDPs), with the #WhatsYourPlan campaign leading to the launch of plans in Uruguay and Armenia, bringing the total number of WHO Member States with NDPs to 41.
Silverado Senior Living is the first care home provider to receive ADI Accreditation since the launch of the accreditation programme in 2021.
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.
Following the launch of the #WhatsYourPlan campaign in November 2021, ADI examines the campaign’s successes in its first year.
Lecanemab is the second Alzheimer’s disease pharmaceutical treatment to come to market since 2003, following the conditional approval of Aduhlem (aducanumab) in June 2022.